RFG Advisory LLC Takes $3.93 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

RFG Advisory LLC purchased a new stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 88,995 shares of the company's stock, valued at approximately $3,927,000. RFG Advisory LLC owned 0.12% of SpringWorks Therapeutics at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Barclays PLC boosted its position in SpringWorks Therapeutics by 60.4% during the third quarter. Barclays PLC now owns 155,676 shares of the company's stock valued at $4,987,000 after acquiring an additional 58,645 shares during the last quarter. SG Americas Securities LLC acquired a new stake in SpringWorks Therapeutics during the fourth quarter worth approximately $210,000. KBC Group NV grew its stake in SpringWorks Therapeutics by 59.1% during the fourth quarter. KBC Group NV now owns 2,634 shares of the company's stock worth $95,000 after purchasing an additional 978 shares during the period. Rhumbline Advisers boosted its holdings in shares of SpringWorks Therapeutics by 2.3% during the 4th quarter. Rhumbline Advisers now owns 101,904 shares of the company's stock worth $3,682,000 after buying an additional 2,251 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D increased its stake in shares of SpringWorks Therapeutics by 19.3% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 55,343 shares of the company's stock valued at $2,000,000 after acquiring an additional 8,954 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Evercore ISI cut shares of SpringWorks Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Monday, April 28th. Guggenheim restated a "neutral" rating and issued a $47.00 target price on shares of SpringWorks Therapeutics in a research note on Monday, May 12th. Cowen downgraded SpringWorks Therapeutics to a "hold" rating in a research note on Tuesday, April 29th. TD Cowen reissued a "hold" rating and issued a $47.00 price objective (down previously from $66.00) on shares of SpringWorks Therapeutics in a research note on Tuesday, April 29th. Finally, HC Wainwright reaffirmed a "neutral" rating and set a $47.00 target price (down from $74.00) on shares of SpringWorks Therapeutics in a research report on Wednesday, April 30th. Seven investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $52.57.

SpringWorks Therapeutics Trading Down 0.0%

Shares of NASDAQ:SWTX traded down $0.01 during mid-day trading on Friday, hitting $46.80. 2,678,345 shares of the company traded hands, compared to its average volume of 2,280,768. SpringWorks Therapeutics, Inc. has a 12-month low of $28.21 and a 12-month high of $62.00. The stock has a market cap of $3.53 billion, a P/E ratio of -13.45 and a beta of 0.77. The stock has a 50-day moving average price of $43.31 and a two-hundred day moving average price of $43.46.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last released its quarterly earnings results on Friday, May 9th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.30). SpringWorks Therapeutics had a negative return on equity of 46.74% and a negative net margin of 134.73%. The firm had revenue of $49.09 million for the quarter, compared to analysts' expectations of $64.19 million. As a group, analysts expect that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current year.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.